Fidson shareholders approve 15kobo/share dividend

In keeping with its policy to give returns for investment, Management of Fidson Healthcare PLC has given its shareholders a dividend of 15 kobo per share.

At the company’s Annual General Meeting for the year 2018 held at the Sheraton Hotels and Towers in Lagos on Thursday, shareholders approved the dividend.

The company recorded an increased turnover of 15 per cent from N14.06 billion in FY 2017 to N16.23 billion in FY 2018. However, because of the increased cost of sales from 49 per cent margin in 2017 to 61 per cent and increased Finance cost (up by 92 per cent), Fidsons’ Profit Before Tax for the period was down to N160.9 million from N1.6bilion in FY 2017.

Having concluded its Rights Issue in June 2019, the company has already taken steps to improve its financial structure. The capital raise was towards refinancing expensive debt and working capital funding in a bid to improve its margins.

ALSO READ: Banks allocate N15.13trn credit to private sector ― NBS

The company continues to leverage its WHO-certifiable factory, having recently executed a partnership with GSK that will see it manufacture for its West African operations going forward. This, alongside market penetration strategy and cost optimisation, are a few of many initiatives to sustain growth and return value to shareholders that the company is currently pursuing.

According to the Chairman of the board, Mr Segun Adebanji, Fidson continues to strengthen its operating facilities with expansion and retooling. ‘’Old machines and equipment have been disused and replaced with modern ones. We are currently expanding our capacity utilisation through increased production and contract manufacturing for other notable companies in the industry’’.

He also said the company is poised to reposition the business through business realignment and useful industry collaboration in order to take advantage of the growth opportunities in the market.


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More